Hospital Universitari de Bellvitge -ko ikertzaileekin lankidetzan egindako argitalpenak (43)

2024

  1. Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)

    Journal of Clinical Medicine, Vol. 13, Núm. 9

  2. Non-atherosclerotic acute cardiac syndromes: spontaneous coronary artery dissection and Takotsubo syndrome. Comparison of long-term clinical outcomes

    Coronary artery disease, Vol. 35, Núm. 1, pp. 50-58

  3. Risk prediction of major cardiac adverse events and all-cause death following covid-19 hospitalization at one year follow-up: The HOPE-2 score

    European Journal of Internal Medicine, Vol. 124, pp. 108-114

2023

  1. Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 1, pp. 77-87

  2. Clinical Profile and Determinants of Mortality in Patients with Interstitial Lung Disease Admitted for COVID-19

    Journal of Clinical Medicine, Vol. 12, Núm. 11

  3. Extended use of dual antiplatelet therapy among older adults with acute coronary syndromes and associated variables: a cohort study

    Thrombosis Journal, Vol. 21, Núm. 1

  4. Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain

    Journal of Clinical Medicine, Vol. 12, Núm. 16

  5. Optimal medical therapy improves outcomes in patients with diabetes mellitus and acute myocardial infarction

    Diabetes Research and Clinical Practice, Vol. 203

  6. Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the International HOPE-II COVID-19 Registry

    Frontiers in Endocrinology, Vol. 14

2022

  1. Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes

    Journal of Clinical Medicine, Vol. 11, Núm. 11

  2. Assessment of medical management in Coronary Type 2 Diabetic patients with previous percutaneous coronary intervention in Spain: A retrospective analysis of electronic health records using Natural Language Processing

    PLoS ONE, Vol. 17, Núm. 2 February

  3. Evaluation of the Use of Dual Antiplatelet Therapy beyond the First Year after Acute Coronary Syndrome

    Journal of Clinical Medicine, Vol. 11, Núm. 6

  4. Major Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing

    Journal of Clinical Medicine, Vol. 11, Núm. 20

  5. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

2021

  1. Evaluation of optimal medical therapy in acute myocardial infarction patients with prior stroke

    Therapeutic Advances in Chronic Disease, Vol. 12

  2. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets

    The Lancet, Vol. 397, Núm. 10270, pp. 199-207

  3. Serum metabolomic analysis suggests impairment of myocardial energy production in takotsubo syndrome

    Metabolites, Vol. 11, Núm. 7

  4. Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries

    Cardiovascular Drugs and Therapy, Vol. 35, Núm. 6, pp. 1171-1182

2020

  1. Antithrombotic Therapy in Patients With Prior Stroke/Transient Ischemic Attack and Acute Coronary Syndromes

    Angiology

  2. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries

    American Heart Journal, Vol. 220, pp. 108-115